Brexpiprazole-d8, CAS 1427049-21-5

Formulation: A solid

Formal Name: 7-[4-(4-benzo[b]thien-4-yl-1-piperazinyl-2,2,3,3,5,5,6,6-d8)butoxy]-2(1H)-quinolinone

Purity: ≥99% deuterated forms (d1-d8)

Formula Markup: C25H19D8N3O2S

Formula Weight: 441,6

Shelf life (days): 730

CAS Number: 1427049-21-5

Notes: Brexpiprazole-d8 is intended for use as an internal standard for the quantification of brexpiprazole (Item No. 22906) by GC- or LC-MS. Brexpiprazole is a serotonin (5-HT) and dopamine receptor modulator that has high affinity (Ki = 1A and 5-HT2A serotonin, dopamine D2L, and α1B-, and α2C-adrenergic receptors in CHO cell membranes expressing the human receptors.{39167} It acts as a partial agonist of 5-HT1A, D2L, and D3 receptors (EC50s = 0.49, 4.0, and 2.8 nM, respectively) and an antagonist of 5-HT2A, 5-HT2B, as well as α1B- and α2C-adrenergic receptors (IC50s = 6.5, 14, 0.66, and 63 nM, respectively) in vitro. In vivo, brexpiprazole dose-dependently reduces conditioned avoidance response (CAR) time, inhibits locomoter hyperactivity induced by apomorphine (Item No. 16094) and amphetamine, and reverses cognitive defects induced by subchronic PCP administration in rats.{39168} It also reduces apomorphine-induced eye blinking in cynomolgus monkeys. Formulations containing brexpiprazole have been used in the treatment of schizophrenia and major depressive disorder.

• Artikelnummer: CAY26450-1
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 26450-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Methode: GC-MS, LC-MS, Isotopenmarkierung